INNATE PHARMA SA (IPHA): Price and Financial Metrics


INNATE PHARMA SA (IPHA)

Today's Latest Price: $5.16 USD

0.14 (2.79%)

Updated Nov 24 4:00pm

Add IPHA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

IPHA Stock Summary

  • IPHA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than merely 6.08% of US-listed equities with positive expected earnings growth.
  • Innate Pharma SA's stock had its IPO on October 18, 2019, making it an older stock than just 0.76% of US equities in our set.
  • With a year-over-year growth in debt of 309.54%, Innate Pharma SA's debt growth rate surpasses 94.83% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Innate Pharma SA are DRRX, VCNX, VNE, CLDX, and PULM.
  • IPHA's SEC filings can be seen here. And to visit Innate Pharma SA's official web site, go to www.innate-pharma.com.

IPHA Stock Price Chart Interactive Chart >

Price chart for IPHA

IPHA Price/Volume Stats

Current price $5.16 52-week high $8.24
Prev. close $5.02 52-week low $3.30
Day low $4.99 Volume 13,100
Day high $5.30 Avg. volume 19,202
50-day MA $4.19 Dividend yield N/A
200-day MA $5.85 Market Cap 407.54M

INNATE PHARMA SA (IPHA) Company Bio


Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells.


IPHA Latest News Stream


Event/Time News Detail
Loading, please wait...

IPHA Latest Social Stream


Loading social stream, please wait...

View Full IPHA Social Stream

Latest IPHA News From Around the Web

Below are the latest news stories about Innate Pharma SA that investors may wish to consider to help them evaluate IPHA as an investment opportunity.

Earnings Scheduled For September 8, 2020

Companies Reporting Before The Bell • China Online Education Group (NYSE: COE ) is projected to report quarterly earnings at $0.11 per share on revenue of $67.54 million. • General Finance (NASDAQ: GFN ) is estimated to report quarterly earnings at $0.03 per share on revenue of $78.75 million. • NAPCO Security (NASDAQ: NSSC ) is expected to report quarterly earnings at $0.18 per share on revenue of $26.46 million. • Innate Pharma (NASDAQ: IPHA ) is expected to report earnings for its second quarter. • Uxin (NASDAQ: UXIN ) is expected to report quarterly loss at $0.09 per share on revenue of … Full story available on Benzinga.com

Benzinga | September 8, 2020

Innate Pharma nabs €6.8M grant for COVID-19 research activities

Innate Pharma (IPHA) has obtained funding of €6.8M under the PSPC-COVID call for projects to support its COVID-19 research and development activities. PSPC-COVID is a program established by the French government to support the development of therapeutic solutions with a preventative or curative aim for COVID-19. As part of this...

Seeking Alpha | August 11, 2020

Innate Pharma Announces the Appointment of Joyson Karakunnel, MD, MSC, FACP as Chief Medical Officer

MARSEILLE, France, July 16, 2020 -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the appointment of Dr..

Yahoo | July 16, 2020

Innate Pharma announces the appointment of Joyson Karakunnel, MD, MSC, FACP as Chief Medical Officer

Pierre Dodion, MD retires as Chief Medical Officer Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the.

Yahoo | July 16, 2020

FDA lifts partial hold on Innate Pharma's lacutamab study

The FDA has lifted partial clinical hold placed on Innate Pharma SA's (IPHA) TELLOMAK Phase II clinical trial, evaluating the efficacy and safety of lacutamab in patients with advanced T-cell lymphomas. The company is taking operational measures to re-activate trial in U.S. The agency's decision is based on a quality assessment...

Seeking Alpha | June 24, 2020

Read More 'IPHA' Stories Here

IPHA Price Returns

1-mo 10.49%
3-mo -19.25%
6-mo -22.41%
1-year -13.42%
3-year N/A
5-year N/A
YTD -19.88%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6824 seconds.